WO2001064177A1 - Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite - Google Patents

Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite

Info

Publication number
WO2001064177A1
WO2001064177A1 PCT/EP2001/002070 EP0102070W WO0164177A1 WO 2001064177 A1 WO2001064177 A1 WO 2001064177A1 EP 0102070 W EP0102070 W EP 0102070W WO 0164177 A1 WO0164177 A1 WO 0164177A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
use according
preparation
substances
cellulite
Prior art date
Application number
PCT/EP2001/002070
Other languages
German (de)
English (en)
Inventor
Ulrich Issberner
Marcus Claas
Vera Maienschein
Silke Nieveler
Thomas Förster
Werner Köhl
Original Assignee
Henkel Kommanditgesellschaft Auf Aktien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Kommanditgesellschaft Auf Aktien filed Critical Henkel Kommanditgesellschaft Auf Aktien
Priority to AU2001246471A priority Critical patent/AU2001246471A1/en
Priority to EP01919334A priority patent/EP1259221A1/fr
Publication of WO2001064177A1 publication Critical patent/WO2001064177A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the invention relates to the use of a composition comprising a flavone, isoflavone or a glycoside thereof and optionally a substance that stimulates and / or depolarizes the C-nerve fibers for the cosmetic or pharmaceutical treatment of cellulite.
  • Cellulite (synonyms: panniculosis, lipodystrophy, status protrusis cutis, orange peel) is a local accumulation of fat and water in body tissue. It is a predominantly aesthetic problem associated with pitting and deepening of the skin and nodulation of the subcutaneous fatty tissue, particularly on the thighs and buttocks. In the context of the present invention, local fat excess weights are also included under the term cellulite. In advanced stages of cellulite, pain in the area of the nodules can also occur. A clear distinction from cellulite is cellulitis (panniculitis), which is an inflammation of the subcutaneous adipose tissue and thus a serious and life-threatening illness in some cases.
  • panniculitis panniculitis
  • the conventional treatment methods for cellulite try to promote blood circulation and have a positive influence on the connective tissue structure, for example through
  • the best known and most widespread of the methods of stimulating lipolysis is to inhibit the enzyme phosphodiesterase in order to prevent or at least slow down the degradation of the cyclic AMP.
  • the phosphodiesterase destroys the cyclic AMP by converting it to 5 ' -AMP, which is no longer able to activate lipolysis. It is therefore important to inhibit the action of the phosphodiesterase in such a way that a high concentration of cyclic AMP is achieved in the region of the adipocytes with the aim of stimulating lipolysis.
  • various phosphodiesterase inhibitors that have been recommended, for example, as slimming agents, are the xanthine bases, especially caffeine.
  • FR 2740681 describes cosmetic compositions for the treatment of cellulite which contain caffeine and an extract from the bark or leaves of plants of the genus Viburnum.
  • Amentoflavon a biflavonoid consisting of two apigenin units, is described as a component of this extract.
  • amentoflavone is a characteristic ingredient of viburnum and serves to standardize the dosage of the viburnum extract in the compositions according to the invention. The document does not give the person skilled in the art any indication that the amentoflavone could be the cause or jointly responsible for the anti-cellulite effect of the compositions.
  • compositions with a local slimming effect which is attributed to their intracellular phosphodiesterase-inhibiting action.
  • the compositions may contain glycosides such as bioflavonoids as additional ingredients. It is not disclosed which substances or groups of substances are to be understood under the term bioflavonoids, which is known to be contradictory in the specialist world. This does not enable the person skilled in the art to prepare a composition according to the teaching of the writing containing a bioflavonoid which has a locally slimming effect. The document also gives no indication that the bioflavonoids could contribute to the slimming properties of the compositions according to the invention.
  • the object of the invention was to remedy the shortcomings of the prior art and to provide improved agents for treating cellulite.
  • the object of the invention is achieved by the use of a composition comprising a flavone, isoflavone or their glycoside and optionally a substance which stimulates and / or depolarizes carbon nerve fibers, for the cosmetic treatment of cellulite or for firming the skin.
  • the invention accordingly furthermore relates to the use of a composition comprising a flavone, isoflavone or their glycoside and, if appropriate, a substance which stimulates and / or depolarizes C-nerve fibers, for the production of a pharmaceutical preparation for the therapeutic treatment of cellulite.
  • flavones are understood to mean substances which are hydrogenation, oxidation or substitution products of 2-phenyl-4H-1-benzopyran, where hydrogenation can be present in the 2,3-position of the carbon skeleton, oxidation under Formation of a carbonyl group may be in the 4-position, and substitution is to be understood as the replacement of one or more hydrogen atoms by hydroxyl or methoxy groups.
  • This definition therefore includes flavans, flavan-3-oles (catechins), flavan-3,4-diols (leucoanthocyanidins), flavones, flavonols and flavanones in the conventional sense.
  • the flavones according to the invention include, for example, chrysin, galangin, apigenin, fisetin, luteolin, camphor oil, quercetin, Mon, Robinetin, Gossypetin, Taxifolin, Myricetin, Rhamnetin, Isorhamnetin, Naringenin, Eriodyctiol, Hesperetin, Liquiritigenin, Catechin and Epicatechin. Quercetin and luteolin are preferred as flavones.
  • the flavones are glycosidically linked to at least one sugar via at least one hydroxyl group.
  • Monosaccharides and oligosaccharides in particular D-glucose, D-galactose, D-glucuronic acid, D-galacturonic acid, D-xylose, D-apiose, L-rhamnose, L-arabinose and rutinose are suitable as sugars.
  • Examples of the flavone glycosides according to the invention are rutin, hesperidin and naringin.
  • isoflavones are understood to mean substances which are hydrogenation, oxidation or substitution products of 3-phenyl-4H-1-benzopyran, where hydrogenation can be present in the 2,3-position of the carbon skeleton, oxidation under Formation of a carbonyl group may be in the 4-position, and substitution is to be understood as the replacement of one or more hydrogen atoms by hydroxyl or methoxy groups.
  • the isoflavones according to the invention include, for example, daidzein, genistein, prunetin, biochanin, Orobol, Santal, pratensein, irigenin, glycitein, biochanin A and formononetin. Daidzein, genistein, glycitein and formononetin are preferred as isoflavones.
  • the isoflavones are glycosidically linked to at least one sugar via at least one hydroxyl group.
  • Suitable sugars are mono- or oligosaccharides, in particular D-glucose, D-galactose, D-glucuronic acid, D-galacturonic acid, D-xylose, D-apiose, L-rhamnose, L-arabinose and rutinose.
  • Preferred examples of the isoflavone glycosides according to the invention are daidzin and genistin.
  • the C-nerve fibers also called polymodal C-nerve fibers, play an important role in the human organism for the sensory functions of the body, especially the skin. They are primarily perception for example from warmth, cold and itching as well as the sensation of pain (e.g. heat pain, cold pain, stinging pain, burning pain).
  • the polymodal C-nerve fibers have a special position as a sub-group of the C-nerve fibers because they can react to several different stimuli and can also intervene in the stimulus process through the release of mediators.
  • Different receptors such as capsaicin, bradykinin and 5-hydroxytryptamine receptors are located on the surface of the C-nerve fibers, as well as ion channels such as calcium and sodium channels, via which the C-nerve fibers can be stimulated and / or depolarized.
  • This stimulation and / or depolarization triggers a sensory stimulus which manifests itself, for example, as a burning sensation, tingling sensation, warmth, coldness or pain.
  • it is preferred to trigger a tingling sensation, a slight burning sensation or a feeling of warmth or coldness by stimulating and / or depolarizing the C-nerve fibers of the skin, in particular by stimulating the capsaicin receptors of these nerve fibers.
  • substances influencing C nerve fibers are to be understood, for example:
  • Preferred substances influencing C-nerve fibers are capsaicin, N-vanillyl nonanamide and their glycosides.
  • An advantage of the preparations according to the invention with substances that stimulate and / or depolarize C-nerve fibers is the generation of a physiological and / or psychological effect which is independent of the treatment effect on cellulite and which the user already has immediately during or after the application of the agent gives a subjective impression of an onset of effect.
  • the improvement in cellulite by the preparations according to the invention is achieved in particular by the breakdown of fat cells and the remodeling of connective tissue, which is why the success of the treatment becomes visible only after prolonged use due to physiological reasons. In practice, however, it has been shown that the users of an anti-cellulite agent very soon stop using the agent and are disappointed with the product used if they do not at least have the subjective impression that the agent has an effect.
  • the presence of substances which stimulate and / or depolarize C-nerve fibers triggers a sensible stimulus in the user, which subjectively gives him an impression of the effect.
  • the substances that influence the C-nerve fibers sometimes have other desired effects. They promote the blood flow to the treated tissue and thus promote the penetration of the ingredients of the preparation into the skin. Furthermore, the removal of the degradation products which arise in the course of the lipolysis which is brought about by the use of the preparation can be promoted. In addition, cellulite in severe cases Pain be dampened. This is the case, for example, when nonivamide (N-vanillyl-nonanamide) is used as the substance influencing the C-nerve fibers.
  • the active substances are used according to the invention in concentrations such that the toxicologically permissible use concentration in preparations or during use is not exceeded.
  • the preparations contain the flavones, isoflavones and their glycosides as constituents of a mixture of substances obtained from a plant, in particular a plant extract.
  • a plant extract obtained from a plant, in particular a plant extract.
  • Such vegetable substance mixtures can be obtained in a manner familiar to the person skilled in the art, for example by pressing or extracting them from plants such as soybean, red clover or chickpeas.
  • Isoflavones or isoflavone glycosides in the form of extracts obtained from soy are particularly preferably used in the preparations according to the invention, such as those known under the product name Soy Protein Isolate SPI (Protein Technology International, St. Louis) or Soy Phytochemicals Concentrate SPC (Archer Daniels Midland, Decatur) are commercially available.
  • Alcohols and mixtures thereof can be used.
  • the alcohols are lower alcohols such as especially ethanol and isopropanol, and polyvalent ones
  • Alcohols such as ethylene glycol, propylene glycol and butylene glycol, both as the sole extracting agent and in a mixture with water, are preferred.
  • Alcoholic extraction is preferred according to the invention.
  • the invention relates to the use of a composition comprising a flavone, isoflavone or their glycoside and, if appropriate, a substance which stimulates and / or depolarizes C-nerve fibers, in combination with a phosphodiesterase inhibitor for the cosmetic treatment of cellulite or for the preparation a pharmaceutical preparation for the therapeutic treatment of cellulite.
  • suitable phosphodiesterase inhibitors are, for example, inhibitors as described in RM Di Salvo, Controlling the Appearance of Cellulite, Cosmetics and Toiletries Magazine 110, pp. 50-59 (1995) or in L. Stryer, Biochemie, Spektrum Akademischer Verlag GmbH, Heidelberg 1991, p. 482.
  • xanthine or a methylxanthine are preferably considered as phosphodiesterase inhibitors, methyl xanthine being a xanthine derivative in which one or more hydrogen atoms are replaced by methyl groups.
  • Theophylline, theobromine and caffeine are preferred as methylxanthines, and caffeine is particularly preferred.
  • the cosmetic or pharmaceutical preparations contain a total of 0.1 to 20% by weight, and preferably 1 to 10% by weight, of one or more flavones, isoflavones or their glycosides and optionally 0.0001 to 3% by weight and preferably 0.005 to 0.5% by weight of one or more substances which stimulate and / or depolarize the C nerve fibers, based on the total weight of the preparation.
  • the cosmetic or pharmaceutical preparations additionally contain a total of 1 to 15% by weight, and preferably 5 to 10% by weight, of one or more phosphodiesterase inhibitors, based on the total weight of the preparation.
  • the combination according to the invention consists of
  • the cosmetic or pharmaceutical preparations contain
  • composition comprising a flavone, isoflavone or their glycoside and optionally a substance which stimulates and / or depolarizes C-nerve fibers, is preferably carried out together with a physiologically tolerable carrier in the form of a cosmetic preparation.
  • the physiologically acceptable carrier of the cosmetic or pharmaceutical preparations comprises one or more adjuvants, as are usually used in such preparations, such as.
  • adjuvants such as.
  • Electrolytes Sequestrants organic solvents, preservatives, bactericides, antioxidants, vitamins, fragrances, flavors, sweeteners, colors and pigments.
  • the cosmetic and pharmaceutical preparations according to the invention are advantageously in the form of a liquid or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, microemulsion, PIT emulsion or Pickering emulsion, a hydrogel, an alcoholic gel, a lipogel, a single or multi-phase solution, a foam, an ointment, a plaster, a suspension, a powder or a mixture with at least one polymer suitable as a medical adhesive.
  • the skin treatment compositions according to the invention can also be administered in anhydrous form, such as, for example, an oil or a balm.
  • the carrier can be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • microemulsions are understood to mean not only the thermodynamically stable microemulsions but also the so-called “PIT” emulsions.
  • PIT phase inversion temperature
  • O / W emulsions are again formed, but these are also present at room temperature as microemulsions or as very fine-particle emulsions with an average particle diameter below 400 nm and in particular from about 100-300 nm.
  • those micro- or "PIT" emulsions can be preferred which have an average particle diameter of approximately 200 nm. Details regarding these "PIT emulsions” e.g. B. the publication Angew. Chem. 97, 655-669 (1985).
  • the pharmaceutical preparations according to the invention are also administered enterally, parenterally or rectally.
  • the pharmaceutical preparations can be in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules or emulsions.
  • the preparations may be in the form of solutions or suspensions for perfusion or injection.
  • the preparations can be in the form of suppositories for administration by the rectal route.
  • Suitable fat substances are for example:
  • vegetable oils such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach seed oil and the liquid components of coconut oil,
  • paraffin oils e.g. 1, 3-di- (2-ethyl-hexyl) cyclohexane (Cetiol ® S) or polydecene,
  • Di-n-alkyl ethers with a total of 12 to 36, in particular 12 to 24 carbon atoms, for.
  • di-n-octyl ether (Cetiol ® OE)
  • di-n-n-hexyl-n-octyl ether di-n-octyl-n-decyl ether.
  • C 8 - 3 o-fatty acids especially linear and / or branched, saturated and / or unsaturated C 8 - 3 o-fatty acids.
  • C ⁇ o- 22 fatty acids are preferred. Examples are the isostearic acids and isopalmitic acids such as the fatty acids sold under the trade name Edenor ® .
  • fatty acids are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, arenachidonic acid, gadachoic acid, gadachoic acid, gadolinic acid, gadachoic acid, gadachoic acid, gadachic acid, gaurachidic acid, gadic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic acidic acid, gaic
  • the fatty acid cuts that are obtainable from coconut oil or palm oil are usually particularly preferred; the use of stearic acid is particularly preferred.
  • Esteröle that is, esters of C 6 - 3 o-fatty acids with C. 2 30 fatty alcohols.
  • the monoesters of fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • the above-mentioned substances can be used as alcohol and acid components of the ester oils.
  • Hydroxycarboxylic acid alkyl esters wherein the Vollester of glycolic acid, lactic acid, malic acid, tartaric acid or citric acid are preferred, but also esters of beta-hydroxypropionic acid, tartronic acid, D-gluconic acid, saccharic acid, mucic acid or glucuronic acid are suitable and particularly preferred are the esters of C ⁇ 2 - C ⁇ 5 fatty alcohols, for. B. are the commercial products Cosmacol ® from EniChem, Augusta Industriale,
  • Dicarboxylic acid esters such as di-n-butyl adipate, di- (2-ethylhexyl) adipate, di- (2-ethylhexyl) succinate and di-isotridecyiacelate as well as diol esters such as ethylene glycol dioleate, ethylene glycol di-isotridecanoate, propylene glycol di (2-ethylhexanoate), propylene glycol -di-isostearate, propylene glycol-di-pelargonate, butanediol-di-isostearate, neopentyl glycol dicaprylate, symmetrical, asymmetrical or cyclic esters of carbonic acid
  • Fatty alcohols e.g. B. glycerol carbonate or dicaprylyl carbonate (Cetiol ® CC), - Mono, - di- and trifatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerin, e.g. B. Monomuls ® 90-O18, Monomuls ® 90-L12 or Cutina ® MD,
  • - Waxes in particular insect waxes such as beeswax and bumblebee wax, plant waxes such as candelilla wax and carnauba wax, fruit waxes, ozone kerit, micro waxes, ceresin, paraffin, triglycerides saturated and optionally hydroxylated Ci 6 - 3 o-fatty acids, such as.
  • Silicone compounds selected from decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane and silicone polymers, which can, if desired, be cross-linked, e.g. B. polydialkylsiloxanes, polyalkylarylsiloxanes, ethoxylated polydialkylsiloxanes, preferably the substances with the INCI name Dimethicone Copolyol, and polydialkylsiloxanes containing amine and / or hydroxy groups.
  • the amount of fatty substances used is 0.1 to 50% by weight, preferably 0.1 to 20% by weight and particularly preferably 0.1 to 15% by weight, in each case based on the total composition.
  • the skin treatment compositions according to the invention can furthermore contain one or more surface-active substances as an emulsifier or dispersant.
  • Emulsifiers cause water or oil-stable adsorption layers to form at the phase interface, which protect the dispersed droplets against coalescence and thus stabilize the emulsion.
  • emulsifiers are therefore made up of a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions.
  • W / O emulsions which are stabilized without hydrophilic emulsifiers are disclosed in the published documents DE 19816665 A1 and DE 19801593 A1.
  • Under an emulsion is a droplet-like distribution (dispersion) of a liquid in another liquid with the use of energy to create stabilizing phase interfaces Understand surfactants.
  • the selection of these emulsifying surfactants or emulsifiers is based on the substances to be dispersed and the particular external phase as well as the fine particle size of the emulsion.
  • Emulsifiers which can be used according to the invention are, for example
  • alkyl (oligo) glucosides e.g. B. the commercially available product Montanov ® 68,
  • Sterols are understood to be a group of steroids which carry a hydroxyl group on the C atom 3 of the steroid structure and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are beta-sitosterol, stigmasterol, campesterol and ergosterol. Sterols, the so-called mycosterols, are also isolated from fungi and yeasts. - Phospholipids, especially the glucose phospholipids, which, for. B. as lecithins or phosphatidylcholines from z. B. egg yolk or plant seeds (e.g. soybeans) are obtained,
  • polyglycerols and polyglycerol preferably Polyglyceryl-2-dipolyhydroxy- stearate (commercial product Dehymuls ® PGPH) and polyglyceryl-3 diisostearate (Lameform ® TGI commercial product)
  • the cosmetic and pharmaceutical preparations according to the invention preferably contain the emulsifiers in amounts of 0.1 to 25% by weight, in particular 0.5-15% by weight, based on the total composition.
  • the skin treatment agents according to the invention can contain organic or mineral or modified mineral light protection filters.
  • the light protection filters are substances which are liquid or crystalline at room temperature and are able to absorb ultraviolet rays and absorb the energy in the form of longer-wave radiation, e.g. B. to release heat again.
  • the UVA and UVB filters can be used both individually and in mixtures. The use of filter mixtures is preferred according to the invention.
  • the organic UV filters used according to the invention are selected from the derivatives of dibenzoylmethane, cinnamic acid esters, diphenylacrylic acid esters, benzophenone, camphor, p-aminobenzoic acid esters, o-aminobenzoic acid esters, salicylic acid esters, benzimidazoles, 1, 3,5-triazines, monomeric and oligomeric 4,4- Diaryl butadiene carboxylic acid esters and carboxamides,
  • the organic UV filters can be oil-soluble or water-soluble. Oil-soluble UV filters which are particularly preferred according to the invention 1- (4-tert-butylphenyl) -3- (4'methoxyphenyl) propane-1, 3-dione (Parsol ® 1789), 1-phenyl-3- (4'-isopropylphenyl) -propane-1, 3- dione, 3- (4 ' -methylbenzylidene) -D, L-camphor, 4- (dimethylamino) -benzoic acid 2-ethylhexyl ester, 4- (dimethylamino) benzoic acid-2-octyl ester, 4- (dimethylamino) -benzoic acid amyl ester, 4- 2-ethylhexyl methoxycinnamate, propyl 4-methoxycinnamate, isopent
  • Preferred water-soluble UV filters are 2-phenylbenzimidazole-5-sulfonic acid and its alkali, alkaline earth, ammonium, alkylammonium, alkanolammonium and glucammonium salts, sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and their Salts, sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-oxo-3-bomylidenemethyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bornylidene) sulfonic acid and their salts.
  • the preferred inorganic light protection pigments according to the invention are finely dispersed metal oxides and metal salts, for example titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc), barium sulfate and zinc stearate.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm. They can have a spherical shape, but it is also possible to use particles which have an ellipsoidal shape or a shape which differs from the spherical shape in some other way.
  • the pigments can also be surface-treated, ie hydrophilized or hydrophobicized. Typical examples are coated titanium dioxide, such as. B.
  • Titanium dioxide T 805 (Degussa) or Eusolex ® T2000 (Merck). Silicones, and in particular trialkoxyoctylsilanes or simethicones, are particularly suitable as hydrophobic coating agents Question. So-called micro- or nanopigments are preferably used in sunscreens. Micronized zinc oxide is preferably used.
  • Contain protein hydrolyzates or their derivatives Contain protein hydrolyzates or their derivatives.
  • animal protein hydrolyzates are e.g. B. elastin, collagen, keratin, silk and milk protein protein hydrolyzates, which may also be in the form of salts.
  • Vegetable protein hydrolyzates e.g. B. soy, wheat, almond, pea, potato and rice protein hydrolyzates.
  • Corresponding commercial products are e.g. B. DiaMin ® (Diamalt), Gluadin ® (Cognis), Lexein ® (Inolex) and Crotein ® (Croda).
  • amino acid mixtures or individual amino acids such as arginine, lysine, histidine or pyrroglutamic acid, which have been obtained in some other way can also be used instead of them.
  • derivatives of protein hydrolyzates e.g. B. in the form of their fatty acid condensation products.
  • Corresponding commercial products are e.g. B. Lamepon ® (Cognis), Gluadin ® (Cognis), Lexein ® (Inolex), Crolastin ® or Crotein ® (Croda).
  • the cosmetic and pharmaceutical preparations according to the invention contain the additional protein hydrolyzates and their derivatives in amounts of 0.01-10% by weight, based on the total composition. Amounts of 0.1 to 5% by weight, in particular 0.1 to 3% by weight, are particularly preferred.
  • the skin treatment compositions according to the invention can furthermore contain mono-, oligo- or polysaccharides or their derivatives.
  • Suitable monosaccharides according to the invention are e.g. B. glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, aliases, old rose, mannose, gulose, idose and talose, the deoxy sugar fucose and rhamnose and amino sugar such as z.
  • Glucose, fructose, galactose, arabinose and fucose are preferred; Glucose is particularly preferred.
  • Suitable oligosaccharides according to the invention are composed of two to ten monosaccharide units, for. B. sucrose, lactose or trehalose.
  • a particularly preferred oligosaccharide is sucrose.
  • honey which predominantly contains glucose and sucrose, is also particularly preferred.
  • Polysaccharides suitable according to the invention are composed of more than ten monosaccharide units.
  • Preferred polysaccharides are the starches made up of ⁇ -D-glucose units and starch degradation products such as amylose, amylopectin and dextrins.
  • Chemically and / or thermally modified starches eg. B. hydroxypropyl starch phosphate, dihydroxypropyl distarch phosphate or the commercial products Dry Flo ® .
  • Dextrans and their derivatives e.g. B. dextran sulfate.
  • nonionic cellulose derivatives such as methyl cellulose, hydroxypropyl cellulose or hydroxyethyl cellulose
  • cationic cellulose derivatives e.g. B. the commercial products Celquat ® and Polymer JR ® , and preferably Celquat ® H 100, Celquat ® L 200 and Polymer JR ® 400 (Polyquaternium-10) and Polyquaternium-24.
  • polysaccharides from fucose units e.g. B. the commercial product Fucogel ® .
  • the polysaccharides composed of amino sugar units, in particular chitins and their deacetylated derivatives, the chitosans and mucopolysaccharides, are particularly preferred.
  • the preferred mucopoly saccharides according to the invention include hyaluronic acid and its derivatives, e.g. B. sodium hyaluronate or dimethylsilanol hyaluronate, and chondroitin and its derivatives, e.g. B. chondroitin sulfate.
  • hyaluronic acid and its derivatives e.g. B. sodium hyaluronate or dimethylsilanol hyaluronate
  • chondroitin and its derivatives e.g. B. chondroitin sulfate.
  • the cosmetic and pharmaceutical preparations according to the invention can contain further plant extracts. They are usually obtained by extracting the entire plant, but in individual cases also exclusively from flowers and / or leaves and / or seeds and / or other parts of plants. posed. According to the invention, the extracts from the meristem, i.e.
  • Algae extracts can also be used to advantage.
  • the algae extracts used according to the invention come from green algae, brown algae, red algae or blue-green algae (cyanobacteria).
  • the algae used for the extraction can be of natural origin as well as obtained through biotechnological processes and, if desired, can be changed compared to the natural form.
  • the organisms can be changed genetically, by breeding or by cultivation in media enriched with selected nutrients.
  • Preferred algae extracts come from seaweed, blue-green algae, from the green algae Codium tomentosum and from the brown algae Fucus vesiculosus.
  • a particularly preferred algae extract comes from blue-green algae of the Spirulina species, which were cultivated in a magnesium-enriched medium.
  • the extracts from spirulina, green tea, aloe vera, meristem, witch hazel, apricot, marigold, guava, sweet potato, lime, mango, kiwi, cucumber, mallow, marshmallow and violet are particularly preferred.
  • the cosmetic and pharmaceutical preparations according to the invention can also contain mixtures of several, in particular two, different plant extracts.
  • the cosmetic and pharmaceutical preparations according to the invention can contain further active ingredients, auxiliaries and additives, for example:
  • Vitamins, provitamins and vitamin precursors from groups A, C, E and F in particular retinol (vitamin Ai) and its esters, e.g. the acetate and the
  • vitamin C ascorbic acid
  • palmitic acid esters glucosides
  • Phosphates of ascorbic acid, tocopherols, especially tocopherol and its esters e.g. B. the acetate, nicotinate, phosphate and succinate; also vitamin F, which is understood to mean essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid;
  • Antioxidants for example amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (e.g. anserine), chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (e.g. anserine)
  • chlorogenic acid and its derivatives e.g.
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate , Thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable doses (e.g. B. pmol to ⁇ mol / kg), further (Me tall) chelators (e.g. B. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • ZnO, ZnSO 4 selenium and its derivatives (e.g. selenium methionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable as antioxidants (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients,
  • Ceramides and pseudoceramides Triterpenes, especially triterpenic acids such as ursolic acid, rosmaric acid, betulinic acid, boswellic acid and bryonolic acid,
  • Monomeric catechins especially catechin and epicatechin, leucoanthocyanidins, catechin polymers (catechin tannins) and gallotannins,
  • - Thickeners e.g. B. gelatin, vegetable gums such as agar agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum or locust bean gum, natural and synthetic clays and layered silicates, e.g. B. bentonite, hectorite, montmorillonite or Laponite ® , fully synthetic hydrocolloids such.
  • B. polyvinyl alcohol, and also Ca, Mg or Zn soaps of fatty acids,
  • Structurants such as maleic acid and lactic acid
  • Solvents, swelling and penetration substances such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerin and diethylene glycol, carbonates, hydrogen carbonates, guanidines, ureas and primary, secondary and tertiary phosphates
  • Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers, pearlescent agents such as ethylene glycol mono- and distearate and PEG-3 distearate,
  • Blowing agents such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 and air.
  • the skin treatment agents according to the invention can contain one or more film-forming, emulsion-stabilizing, thickening or adhesive polymers, selected from natural and synthetic polymers, which can be cationic, anionic, amphoteric or non-ionic.
  • cationic polymers are polysiloxanes with quaternary groups, e.g. B. the commercial products Q2-7224 (Dow Corning), Dow Corning ® 929 emulsion (with Amodimethicone), SM-2059 (General Electric), SLM-55067 (Wacker) and Abil ® -Quat 3270 and 3272 (Th. Goldschmidt).
  • Preferred anionic polymers which can support the action of the active ingredient used according to the invention contain carboxylate and / or sulfonate groups and, for example, acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid as monomers.
  • the acidic groups can be present in whole or in part as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • anionic polymers contain 2-acrylamido-2-methylpropanesulfonic acid as the sole monomer or as comonomer, it being possible for the sulfonic acid group to be wholly or partly in salt form.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are acrylamide, methacrylamide, acrylic acid ester, methacrylic acid ester, vinyl pyrrolidone, vinyl ether and vinyl ester.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with monomers containing sulfonic acid groups.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, the sulfonic acid groups being wholly or partly as sodium, potassium, ammonium, mono- or triethanolammonium Salt.
  • This copolymer can also be crosslinked, the crosslinking agents preferably being polyolefinic Unsaturated compounds such as tetraallyloxyethane, allyl sucrose, allylpentaerythritol and methylene bisacrylamide are used.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • the use of this compound has proven to be particularly advantageous in the context of the teaching according to the invention.
  • Polysorbate-80 sodium acryloyldimethyltaurate copoly- mers have proven effective as inventively particularly.
  • Other particularly preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene can be preferred crosslinking agents.
  • Such compounds are, for example, the commercial products Carbopol ® .
  • a particularly preferred anionic copolymer contains 80-98% of an unsaturated, optionally substituted C 3 as monomer. 6- carboxylic acid or its anhydride and, if desired, 2 to 20% substituted acrylic acid esters of saturated C 1 -C 30 -carboxylic acids, it being possible for the copolymer to be crosslinked with the aforementioned crosslinking agents.
  • Corresponding commercial products are Pemulen ® and the Carbopol ® types 954, 980, 1342 and ETD 2020 (ex BF Goodrich).
  • Suitable nonionic polymers are, for example, polyvinyl alcohols, which can be partially saponified, e.g. B. the commercial products Mowiol ® and vinyl pyrrolidone vinyl ester copolymers and polyvinyl pyrrolidones, which, for. B. are sold under the trademark Luviskol ® (BASF).
  • Further additives to the cosmetic or pharmaceutical skin treatment agents are selected from the vitamins, provitamins or vitamin precursors of the vitamin B group or their derivatives and the derivatives of 2-furanone.
  • the vitamin B group or the vitamin B complex include, among others
  • Vitamin Bi common name thiamine, chemical name 3 - [(4 ' -amino-2 ' - methyl-5 ' -pyrimidinyl) -methyl] -5- (2-hydroxyethyl) -4-methylthiazolium chloride.
  • Thiamine hydrochloride is preferably used in amounts of 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 2 common name riboflavin, chemical name 7,8-dimethyl-10- (1-D-ribityl) -benzo [g] pteridine-2,4 (3 / - /, 10 / - /) - dione.
  • riboflavin comes e.g. B. in whey before, other riboflavin derivatives can be isolated from bacteria and yeast.
  • a stereoisomer of riboflavin which is also suitable according to the invention is lyxoflavin which can be isolated from fishmeal or liver and which carries a D-arabityl radical instead of D-ribityl.
  • Riboflavin or its derivatives are preferably used in amounts of 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 3 • Vitamin B 3 .
  • the compounds nicotinic acid and nicotinamide (niacinamide) are often listed under this name.
  • the nicotinamide which is present in the cosmetic and pharmaceutical preparations according to the invention preferably in amounts of 0.05 to 1% by weight, based on the total composition, is preferred according to the invention.
  • Vitamin B 5 pantothenic acid and panthenol
  • Panthenol is preferably used.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and cationically derivatized panthenols.
  • derivatives of 2-furanone with the general structural formula (I) can also be used.
  • the 2-furanone derivatives in which the substituents R 1 to R 6 independently of one another are a hydrogen atom, a hydroxyl radical, a methyl, methoxy, aminomethyl or hydroxymethyl radical, a saturated or mono- or di-unsaturated, linear or branched C 2 -C 4 - hydrocarbon radical, a saturated or mono- or di-unsaturated, represent branched or linear mono-, di- or trihydroxy-C 2 -C 4 - hydrocarbon residue or a saturated or mono- or di-unsaturated, branched or linear mono-, di- or triamino-C 2 -C 4 - hydrocarbon residue.
  • Particularly preferred derivatives are the commercially available substances dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone with the common name pantolactone (Merck), 4-hydroxymethyl- ⁇ -butyrolactone (Merck), 3.3 -Dimethyl-2-hydroxy- ⁇ -butyrolactone (Aldrich) and 2,5-dihydro-5-methoxy-2-furanone (Merck), all stereoisomers being expressly included.
  • the 2-furanone derivative which is extremely preferred according to the invention is pantolactone (dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone), wherein in formula (I) R 1 is a hydroxyl group, R 2 is a hydrogen atom , R 3 and R 4 represent a methyl group and R 5 and R 6 represent a hydrogen atom.
  • the stereoisomer (R) - pantolactone is formed when pantothenic acid is broken down.
  • the above-mentioned compounds of the vitamin B 5 type and the 2-furanone derivatives are preferably present in the cosmetic and pharmaceutical preparations according to the invention in a total amount of 0.05 to 10% by weight, based on the total composition. Total amounts of 0.1 to 5% by weight are particularly preferred.
  • Vitamin B ⁇ which does not mean a uniform substance, but rather the derivatives of 5-hydroxymethyl-2-methylpyhdin-3-ol known under the common names pyridoxine, pyridoxamine and pyridoxal.
  • Vitamin B 6 is contained in the cosmetic and pharmaceutical preparations according to the invention preferably in amounts of 0.0001 to 1.0% by weight, in particular in amounts of 0.001 to 0.01% by weight.
  • Vitamin B 7 also known as vitamin H or "skin vitamin”.
  • Biotin is (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-] imidazole-4-valeric acid.
  • the cosmetic and pharmaceutical preparations according to the invention preferably contain biotin in amounts of 0.0001 to 1.0% by weight, in particular in amounts of 0.001 to 0.01% by weight.
  • Panthenol, pantolactone, nicotinamide and biotin are very particularly preferred according to the invention.
  • the cosmetic preparations used according to the invention are preferably suitable for the cosmetic treatment of cellulite and local excess fat, but also for use in so-called "slimming products" and for tightening the skin, in particular the skin of legs, décolleté, neck or in the facial area.
  • Another object of the invention is the use of a composition comprising a flavone, isoflavone or their glycoside and optionally a substance which stimulates and / or depolarizes C-nerve fibers for the production of a preparation for the therapeutic treatment of cellulite.
  • the active ingredients of the three groups mentioned above, optionally in combination with other active substances, together with one or more inert customary carriers and / or diluents for. B. with corn starch, milk sugar, cane sugar, sorbitol, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water / polyethylene glycol, propylene glycol, carboxymethyl cellulose or fatty substances such as hard fat or the like suitable mixtures, work into conventional galenical preparations such as tablets, dragees, capsules, powders, suspensions, drops, ampoules, juices or suppositories.
  • the daily dosage of the active ingredient or mixture of active ingredients required to achieve a corresponding effect in pharmaceutical applications is advantageously 0.1 to 10 mg / kg body weight, preferably 0.5 to 2 mg / kg body weight.
  • compositions according to the invention are preferably suitable for the therapeutic treatment of cellulite.
  • the compositions according to the invention are prepared in that the aqueous phase, which contains water-soluble active ingredients and ingredients and, if appropriate, water-soluble emulsifiers, and the oil phase which contains fats, oils, oil-soluble active ingredients and optionally oil-soluble emulsifiers, at a temperature of 10 to 90 ° C are mixed intensively.
  • the anti-cellulite gel according to Example 1 with the formulation Gel-5 was tested for its effectiveness in relation to the cellulite phenomenon and its cosmetic acceptance in 25 women (half-side test against placebo).
  • the test participants were asked directly after the use test about the effectiveness of the product and the cosmetic acceptance in a standardized way.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une composition contenant une flavone, une isoflavone ou leur glycoside, et éventuellement une substance stimulant et/ou dépolarisant des fibres nerveuses C, dans des compositions de traitement cosmétique ou pharmaceutique de la cellulite.
PCT/EP2001/002070 2000-02-28 2001-02-23 Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite WO2001064177A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001246471A AU2001246471A1 (en) 2000-02-28 2001-02-23 Use of flavones or isoflavones for the treatment of cellulite
EP01919334A EP1259221A1 (fr) 2000-02-28 2001-02-23 Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10009424A DE10009424A1 (de) 2000-02-28 2000-02-28 Verwendung von Flavonen oder Isoflavonen zur Cellulite-Behandlung
DE10009424.4 2000-02-28

Publications (1)

Publication Number Publication Date
WO2001064177A1 true WO2001064177A1 (fr) 2001-09-07

Family

ID=7632757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002070 WO2001064177A1 (fr) 2000-02-28 2001-02-23 Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite

Country Status (4)

Country Link
EP (1) EP1259221A1 (fr)
AU (1) AU2001246471A1 (fr)
DE (1) DE10009424A1 (fr)
WO (1) WO2001064177A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180331A1 (fr) * 2000-08-16 2002-02-20 Unilever N.V. Melanges de isoflavones et flavones
US6617349B2 (en) 2000-08-16 2003-09-09 Lipton, Division Of Conopco, Inc. Blends of isoflavones and flavones
DE10218476A1 (de) * 2002-04-25 2003-11-06 Beiersdorf Ag Zubereitungen mit Lignanen
FR2841470A1 (fr) * 2002-06-27 2004-01-02 Pharmascience Lab Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
WO2004064712A2 (fr) * 2003-01-17 2004-08-05 Beiersdorf Ag Préparations cosmétiques et dermatologiques contenant des extraits de germe de graines de soja en combinaison avec de la vitamine c et / ou e ainsi que de la $g(a)-glycosylrutine
EP1541127A1 (fr) * 2003-12-10 2005-06-15 L'oreal Utilisation des modulateurs d'aquaglycéroporines comme amincissant
FR2868701A1 (fr) * 2004-04-07 2005-10-14 Provital S A Sa Composition cosmetique et/ou pharmaceutique, a action regulatrice de la proportion de graisse contenue dans les adipocytes et/ou a action regulatrice de la differenciation adipocytaire
JP2006527725A (ja) * 2003-06-17 2006-12-07 ディーエスエム アイピー アセッツ ビー．ブイ． フィタン酸またはその誘導体を含む局所用薬剤
FR2919501A1 (fr) * 2007-08-02 2009-02-06 Oreal Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
WO2014091146A2 (fr) 2012-12-11 2014-06-19 Isp Investments Inc. Utilisation cosmetique d'un extrait de germe de caroube en tant qu'agent actif amincissant
WO2014091147A2 (fr) 2012-12-11 2014-06-19 Isp Investments Inc. Utilisation cosmetique de l'association d'un extrait de germe de caroube et de cafeine en tant qu'agent actif amincissant
WO2018048892A1 (fr) 2016-09-07 2018-03-15 Isp Investments Llc Procédé d'augmentation de la lipolyse au moyen d'une composition comprenant un extrait de nelumbo nucifera (lotus) bioactif
EP3970691A1 (fr) 2020-09-18 2022-03-23 C.F.E.B. Sisley Compositions cosmétiques amincissantes contenant un ou plusieurs limonoïdes

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1321123A1 (fr) * 2001-12-20 2003-06-25 Cognis France S.A. Utilisation d'un extrait de Baptisia tinctoria dans une composition cosmétiques
FR2869229B1 (fr) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
DE102004032837A1 (de) * 2004-07-02 2006-02-09 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
MX2007007015A (es) 2004-12-14 2007-07-04 Menarini Ricerche Spa Composiciones farmaceuticas para el tratamiento de celulitis.
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
DE102006008730A1 (de) * 2006-02-22 2007-08-23 Beiersdorf Ag Verwendung von Hydroxymatairesinol zur Verbesserung der Hautkonturen
US20090209637A1 (en) * 2006-08-30 2009-08-20 Christophe Carola Use of chromen-4-one derivatives
DE102006050984A1 (de) * 2006-10-26 2008-04-30 Henkel Kgaa Leistungsgesteigerte kosmetische Mittel mit Purin und/oder Purinderivaten
WO2021085293A1 (fr) * 2019-10-30 2021-05-06 東洋精糖株式会社 Préparation externe pour la peau destinée à atténuer la cellulite et procédé permettant d'atténuer la cellulite

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2205315A1 (en) * 1972-11-07 1974-05-31 Chicouri Marcel Jacques Anticellulitic ointment - contg. folliculinum 3 CH, fucus vesiculorus TM and Hedera helix TM
FR2233071A1 (en) * 1973-06-14 1975-01-10 Prod Hyg Laboratoires Flavones and saponins extracted from ivy - by solid-liquid extraction of undesirables followed by alcohol extraction
FR2578165A1 (fr) * 1985-01-22 1986-09-05 Chicouri Marcel Nouvelles pommades a action anticellulitique.
FR2740681A1 (fr) * 1995-11-07 1997-05-09 Fabre Pierre Dermo Cosmetique Composition cosmetique a base d'un extrait de viburnum
WO1998000101A1 (fr) * 1996-06-27 1998-01-08 Indústria e Comércio de Cosméticos Natura Ltda. Compositions cosmetiques pour le soin de la peau, notamment comme agent anticellulite ou reducteur de cellulite
WO1999047118A1 (fr) * 1998-03-16 1999-09-23 The Procter & Gamble Company Compositions pour modifier l'aspect exterieur de la peau
WO2000001351A1 (fr) * 1998-07-07 2000-01-13 Transdermal Technologies, Inc. Compositions d'administration transdermique rapide et non irritante d'agents pharmaceutiques actifs et methodes pour la formulation de ces compositions et leur administration
FR2786096A1 (fr) * 1998-11-20 2000-05-26 Jean Pascal Conduzorgues Composition pour la prevention et le traitement topique de la cellulite
EP1020192A2 (fr) * 1999-01-11 2000-07-19 Michael Schneider Composition anti-cellulitique
WO2001024806A1 (fr) * 1999-10-01 2001-04-12 Pierre Fabre Dermo-Cosmetique Extraits de branches de pommiers utiles en dermocosmetologie et leur procede de preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3667503B2 (ja) * 1997-08-26 2005-07-06 花王株式会社 皮膚化粧料
FR2778663B1 (fr) * 1998-05-15 2001-05-18 Coletica Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2205315A1 (en) * 1972-11-07 1974-05-31 Chicouri Marcel Jacques Anticellulitic ointment - contg. folliculinum 3 CH, fucus vesiculorus TM and Hedera helix TM
FR2233071A1 (en) * 1973-06-14 1975-01-10 Prod Hyg Laboratoires Flavones and saponins extracted from ivy - by solid-liquid extraction of undesirables followed by alcohol extraction
FR2578165A1 (fr) * 1985-01-22 1986-09-05 Chicouri Marcel Nouvelles pommades a action anticellulitique.
FR2740681A1 (fr) * 1995-11-07 1997-05-09 Fabre Pierre Dermo Cosmetique Composition cosmetique a base d'un extrait de viburnum
WO1998000101A1 (fr) * 1996-06-27 1998-01-08 Indústria e Comércio de Cosméticos Natura Ltda. Compositions cosmetiques pour le soin de la peau, notamment comme agent anticellulite ou reducteur de cellulite
WO1999047118A1 (fr) * 1998-03-16 1999-09-23 The Procter & Gamble Company Compositions pour modifier l'aspect exterieur de la peau
WO2000001351A1 (fr) * 1998-07-07 2000-01-13 Transdermal Technologies, Inc. Compositions d'administration transdermique rapide et non irritante d'agents pharmaceutiques actifs et methodes pour la formulation de ces compositions et leur administration
FR2786096A1 (fr) * 1998-11-20 2000-05-26 Jean Pascal Conduzorgues Composition pour la prevention et le traitement topique de la cellulite
EP1020192A2 (fr) * 1999-01-11 2000-07-19 Michael Schneider Composition anti-cellulitique
WO2001024806A1 (fr) * 1999-10-01 2001-04-12 Pierre Fabre Dermo-Cosmetique Extraits de branches de pommiers utiles en dermocosmetologie et leur procede de preparation

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617349B2 (en) 2000-08-16 2003-09-09 Lipton, Division Of Conopco, Inc. Blends of isoflavones and flavones
EP1180331A1 (fr) * 2000-08-16 2002-02-20 Unilever N.V. Melanges de isoflavones et flavones
DE10218476A1 (de) * 2002-04-25 2003-11-06 Beiersdorf Ag Zubereitungen mit Lignanen
FR2841470A1 (fr) * 2002-06-27 2004-01-02 Pharmascience Lab Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
WO2004002435A2 (fr) * 2002-06-27 2004-01-08 Laboratoires Expanscience Utilisation d'isoflavones pour favoriser l'amincissement
WO2004002435A3 (fr) * 2002-06-27 2004-05-13 Expanscience Lab Utilisation d'isoflavones pour favoriser l'amincissement
WO2004064712A2 (fr) * 2003-01-17 2004-08-05 Beiersdorf Ag Préparations cosmétiques et dermatologiques contenant des extraits de germe de graines de soja en combinaison avec de la vitamine c et / ou e ainsi que de la $g(a)-glycosylrutine
WO2004064712A3 (fr) * 2003-01-17 2005-03-03 Beiersdorf Ag Préparations cosmétiques et dermatologiques contenant des extraits de germe de graines de soja en combinaison avec de la vitamine c et / ou e ainsi que de la $g(a)-glycosylrutine
JP2006527725A (ja) * 2003-06-17 2006-12-07 ディーエスエム アイピー アセッツ ビー．ブイ． フィタン酸またはその誘導体を含む局所用薬剤
EP1541127A1 (fr) * 2003-12-10 2005-06-15 L'oreal Utilisation des modulateurs d'aquaglycéroporines comme amincissant
FR2863492A1 (fr) * 2003-12-10 2005-06-17 Oreal Utilisation des modulateurs d'aquaglyceroporines comme amincissant
FR2868701A1 (fr) * 2004-04-07 2005-10-14 Provital S A Sa Composition cosmetique et/ou pharmaceutique, a action regulatrice de la proportion de graisse contenue dans les adipocytes et/ou a action regulatrice de la differenciation adipocytaire
FR2919501A1 (fr) * 2007-08-02 2009-02-06 Oreal Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
WO2009022077A3 (fr) * 2007-08-02 2010-02-11 L'oreal Utilisation d'hespéridine ou de l'un de ses dérivés pour la prévention et/ou le traitement des peaux relâchées
WO2014091146A2 (fr) 2012-12-11 2014-06-19 Isp Investments Inc. Utilisation cosmetique d'un extrait de germe de caroube en tant qu'agent actif amincissant
WO2014091147A2 (fr) 2012-12-11 2014-06-19 Isp Investments Inc. Utilisation cosmetique de l'association d'un extrait de germe de caroube et de cafeine en tant qu'agent actif amincissant
US9962329B2 (en) 2012-12-11 2018-05-08 ISP Investments, LLC Cosmetic use of the combination of a carob germ extract and caffeine as a slimming active agent
WO2018048892A1 (fr) 2016-09-07 2018-03-15 Isp Investments Llc Procédé d'augmentation de la lipolyse au moyen d'une composition comprenant un extrait de nelumbo nucifera (lotus) bioactif
EP3970691A1 (fr) 2020-09-18 2022-03-23 C.F.E.B. Sisley Compositions cosmétiques amincissantes contenant un ou plusieurs limonoïdes
FR3114241A1 (fr) 2020-09-18 2022-03-25 C F E B Sisley Compositions cosmétiques amincissantes contenant un ou plusieurs limonoïdes

Also Published As

Publication number Publication date
DE10009424A1 (de) 2001-09-06
EP1259221A1 (fr) 2002-11-27
AU2001246471A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
WO2001064177A1 (fr) Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite
DE10333245C5 (de) Präbiotisch wirksame Pflanzenextrakte
EP1658088B1 (fr) Composition avec un effect prebiotique comprenant des extraits de pinus sylvestris et de ribes nigrum pour l'inhibition de la croissance de priopionibacterium acnes
DE10063433A1 (de) Verwendung von DNA-Reparatur-Enzymen als MMP-1-Inhibitoren
DE602004003587T2 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
DE4341000A1 (de) Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
EP1352640A1 (fr) Compositions pouvant retarder le vieillissement de la peau
WO1998017246A1 (fr) Utilisation de complexes pour la preparation de compositions de traitement de peaux sensibles, procede de preparation et compositions hypoallergenes
DE60219782T2 (de) Pharmazeutische und/oder kosmetische zusammensetzung zur behandlung von lokaler adipositas und zellulitis
EP1261310A1 (fr) Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite
JPH07223933A (ja) 美白剤および皮膚外用剤
DE602004006271T2 (de) Kombination vasoaktiver agentien und deren verwendung zur behanldung sexueller störungen
EP2533752A1 (fr) Préparations pour stabiliser/élaborer la texture d'un tissu vivant comme la peau, et leurs applications
JP3900388B2 (ja) 美白剤および美白化粧料
KR101830864B1 (ko) 탈모방지 또는 모발 성장 촉진용 화장료 조성물
CN112569163B (zh) 一种不含防腐剂的抗敏修复乳液及其制备方法
EP2223679A2 (fr) Compositions rajeunissant les cellules
EP1667641A1 (fr) Preparations cosmetiques ou dermatologiques a teneur en isoflavones et en licochalcone a
EP1377254A2 (fr) Preparations cosmetiques et dermatologiques contenant des isoflavones
EP4059508A1 (fr) Procédés d'utilisation de compositions comprenant un extrait de lichen d'islande
KR102142931B1 (ko) 붉나무 열매 추출물을 포함하는 피지분비 억제용 조성물
DE10340684A1 (de) Neue Verwendungen von Vitamin B6 in kosmetischen oder pharmazeutischen Zusammensetzungen
KR20230143023A (ko) 시지지움 포르모슘 추출물을 유효성분으로 포함하는 피부 개선용 조성물
KR20230076873A (ko) 쑥속 식물 추출물을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물
DE102020004093A1 (de) Zusammensetzung zur Behandlung von Haaren und der Kopfhaut

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ HU JP MX NO PL SK US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001919334

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001919334

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001919334

Country of ref document: EP